Basilio Garcia-Selleck, DO
Family Medicine · Miami, FLNPI 1871643262
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 434 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $4,641 and has fallen 81.7% since, to $849 in 2025. Among family medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 434 payments — averaging $32.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Novo Nordisk$1K
- Astellas Pharma US Inc$1K
- Amarin Pharma, Inc.$878
- Esperion Therapeutics, Inc.$833
- plus $7K from 25 others
Across 76 payments — averaging $6718.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$270K
- GSK$109K
- Chiesi USA, Inc.$90K
- Novartis$28K
- Acadia Pharmaceuticals Inc$14K
What the payments were for
- Food & beverage$13,89597%
- Education$3973%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 73 | $2,116 |
| AstraZeneca | 25 | $1,462 |
| Novo Nordisk | 38 | $1,231 |
| Astellas Pharma US Inc | 35 | $1,025 |
| Amarin Pharma, Inc. | 49 | $878 |
| Esperion Therapeutics, Inc. | 11 | $833 |
| Pfizer | 17 | $802 |
| AbbVie(2 entities) | 42 | $767 |
| Johnson & Johnson | 13 | $763 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 37 | $660 |
| Boehringer Ingelheim | 10 | $504 |
| Sanofi-aventis U.S. LLC | 8 | $498 |
| Eisai Inc. | 7 | $465 |
| Novartis | 9 | $311 |
| Bayer | 4 | $276 |
| Abbott | 4 | $230 |
| Corcept Therapeutics | 8 | $229 |
| Phathom Pharmaceuticals, Inc. | 4 | $207 |
| Lilly USA, LLC | 10 | $182 |
| Amgen | 3 | $160 |
| Ironwood Pharmaceuticals, Inc | 1 | $114 |
| Genentech USA, Inc. | 6 | $111 |
| Exact Sciences | 4 | $105 |
| Merck | 2 | $85 |
| E.r. Squibb & Sons, L.L.C. | 4 | $81 |
| Kowa Pharmaceuticals America, Inc. | 3 | $62 |
| Sunovion Pharmaceuticals Inc. | 3 | $53 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Medtronic | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,292 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $21,100 |
| VascepaIcosapent Ethyl | 24 | $14,972 |
| TradjentaLinagliptin | 16 | $12,624 |
| JardianceEmpagliflozin | 19 | $11,235 |
| OzempicSemaglutide | 11 | $10,525 |
| SynthroidLevothyroxine Sodium | 20 | $2,640 |
| Levemir FlexpenInsulin Detemir | 13 | $1,735 |
| Rosuvastatin Calcium | 76 | $1,592 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,388 |
| Fenofibrate | 65 | $1,248 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 19 | $1,091 |
| Losartan Potassium | 78 | $1,027 |
| Nebivolol Hcl | 19 | $979 |
| Famotidine | 70 | $914 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 16 | $910 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta, Jardiance | $504 | $23,85835 claims |
| PfizerEliquis | $802 | $21,10020 claims |
| Novo NordiskOzempic | $1,231 | $10,52511 claims |
| AbbVieSynthroid | $767 | $2,64020 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $18 | $57252 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Miami
- Clifford KinderMiami$75K
- Robert GoubeauxMiami$67K
- Vanessa RojasMiami$50K
- Michelle PowellMiami$34K
- Ana EloseguiMiami$32K
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.